oxybutynin has been researched along with tolterodine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aeron, S; Bruhaspathy, M; Chugh, A; Gupta, JB; Gupta, S; Hegde, LH; Kaur, K; Kumar, N; Mehta, A; Sarma, PK; Shetty, SJ; Silamkoti, AD | 1 |
| Ikeda, K; Naito, R; Okamoto, Y; Takeuchi, M; Toyoshima, A; Yonetoku, Y | 1 |
| Chimmanamada, D; Christophe, B; Collart, P; Guyaux, M; Jadot, S; Lo Brutto, P; Massingham, R; Mioskowski, C; Quéré, L; Starck, JP; Talaga, P; Wagner, A; Zanda, M | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Babu, V; Bansal, V; Chugh, A; Garg, M; Gupta, S; Krishna, NS; Kumar, N; Malhotra, S; Meru, AV; Ray, A; Sinha, S | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for oxybutynin and tolterodine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for oxybutynin and tolterodine
| Article | Year |
|---|---|
Design, synthesis and activity of novel derivatives of oxybutynin and tolterodine.
Topics: Animals; Benzhydryl Compounds; Binding Sites; Cresols; Drug Design; Mandelic Acids; Phenylpropanolamine; Rats; Receptor, Muscarinic M2; Receptor, Muscarinic M3; Structure-Activity Relationship; Tolterodine Tartrate | 2005 |
Synthesis and antimuscarinic properties of quinuclidin-3-yl 1,2,3,4-tetrahydroisoquinoline-2-carboxylate derivatives as novel muscarinic receptor antagonists.
Topics: Animals; Female; Models, Molecular; Muscarinic Antagonists; Muscle Contraction; Muscle, Smooth; Quinuclidines; Radioligand Assay; Rats; Rats, Wistar; Receptor, Muscarinic M3; Saliva; Solifenacin Succinate; Stereoisomerism; Structure-Activity Relationship; Tetrahydroisoquinolines; Urinary Bladder; Urinary Incontinence | 2005 |
Potent anti-muscarinic activity in a novel series of quinuclidine derivatives.
Topics: Animals; Binding Sites; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Drug Evaluation, Preclinical; Guinea Pigs; Humans; In Vitro Techniques; Microsomes; Molecular Structure; Muscarinic Antagonists; Quinuclidines; Receptors, Muscarinic; Structure-Activity Relationship | 2006 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
AE9C90CB: a novel, bladder-selective muscarinic receptor antagonist for the treatment of overactive bladder.
Topics: Animals; Brain; Bridged Bicyclo Compounds, Heterocyclic; Carbachol; Cell Line, Transformed; CHO Cells; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Male; Mice; Muscarinic Antagonists; Rabbits; Rats; Salivary Glands; Urinary Bladder, Overactive | 2010 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |